Biocon Biologics: US Biosimilars Are A Marathon, Not A Sprint

As Biocon Biologics makes multiple moves to position its recently-integrated US biosimilars business for success, the firm’s chief commercial officer for advanced markets, Matt Erick, tells Generics Bulletin that US biosimilar competition is a “marathon” that is “not going to be won in the short term.”